Brief reportRetinopathy in Persons With Impaired Glucose Metabolism: The Australian Diabetes Obesity and Lifestyle (AusDiab) Study
References (7)
- et al.
Retinal microvascular abnormalities, and their relation to hypertension, cardiovascular diseases and mortality
Surv Ophthalmol
(2001) - et al.
Retinal microvascular abnormalities and incident clinical strokesthe Atherosclerosis Risk in the Communities Study
Lancet
(2001) - et al.
The Australian Diabetes, Obesity and Lifestyle Study (AusDiab)—methods and response rates
Diabetes Res Clin Pract
(2002)
Cited by (0)
Supported in part by Commonwealth Department of Health and Aged Care, Abbott Australasia Pty Ltd, Alphapharm Pty Ltd, Aventis Pharmaceutical, AstraZeneca, Bristol-Myers Squibb Pharmaceuticals, Eli Lilly (Aust) Pty Ltd, GlaxoSmithKline, Janssen–Cilag (Aust) Pty Ltd, Merck Lipha sa, Merck Sharp & Dohme (Aust), Novartis Pharmaceutical (Aust) Pty Ltd, Novo Nordisk Pharmaceutical Pty Ltd, Pharmacia and Upjohn Pty Ltd, Pfizer Pty Ltd, Roche Diagnostics, Sanofi Synthelabo (Aust) Pty Ltd, Servier Laboratories (Aust) Pty Ltd, BioRad Laboratories Pty Ltd, HITECH Pathology Pty Ltd, the Australian Kidney Foundation, Diabetes Australia, Diabetes Australia (Northern Territory), Queensland Health, South Australian Department of Human Services, Tasmanian Department of Health and Human Services, Territory Health Services, Victorian Department of Human Services and Health Department of Western Australia. The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the article in manuscript.